---
noindex: true
sitemap: false
layout: default
title: Abiraterone Acetate
parent: Low Evidence (L5)
nav_order: 24
evidence_level: L5
indication_count: 0
last_modified_at: 2026-11-06
predicted_indications: []
---

# Abiraterone Acetate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Abiraterone Acetate: Evidence Pack Incomplete — Evaluation on Hold
{: .text-alpha }

## One-Sentence Summary

Abiraterone Acetate is a drug identified for drug repurposing evaluation, but the current Evidence Pack contains no predicted indications, no safety information. Without predicted indication targets or supporting evidence, a substantive repurposing evaluation cannot be conducted at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | None — TxGNN prediction results not included |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (Model prediction only — no actual studies retrievable) |
| Singapore Market Status | Marketed (valid licences: 17 of 17) |
| Number of Registrations | 17 (valid: 17) |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (flagged as Data Gap DG002). No original indications have been recorded, and no TxGNN predicted indication has been returned in the `predicted_indications` field.

A DrugBank query was executed on 2026-03-26 and returned one result (`result_count: 1`), indicating that DrugBank data for this compound does exist and can be retrieved. However, the MOA and pharmacological category data were not successfully populated into the Evidence Pack. This should be the first priority for remediation.

Without MOA data, it is not possible to establish a mechanistic rationale connecting Abiraterone Acetate to any new indication, nor to assess pharmacological plausibility for repurposing.

---

## Clinical Trial Evidence

Currently no related clinical trials registered under any predicted indication (no predicted indications available in this Evidence Pack).

---

## Literature Evidence

Currently no related literature available (no predicted indications available to anchor a literature search).

---

## Singapore Market Information

| Licence | Product | Dosage form | Status |
|------|------|------|------|
| SIN14146P | Zytiga Tablet 250 mg | TABLET | Valid |
| SIN15345P | ZYTIGA FILM-COATED TABLET 500MG | TABLET, FILM COATED | Valid |
| SIN15833P | ABIRANAT TABLETS 250MG USP | TABLET | Valid |
| SIN15933P | ONCOPROS - ABIRATERONE ACETATE TABLETS USP 250MG | TABLET | Valid |
| SIN16002P | ABIRATRED ABIRATERONE ACETATE FILM COATED TABLET USP 250MG | TABLET, FILM COATED | Valid |

Showing 5 of 17 HSA registrations.

---

## Safety Considerations

Please refer to the package insert for safety information.

No safety data is available in this Evidence Pack:
- Key warnings: not populated
- Contraindications: not populated
- Drug-drug interactions: query returned no results (DDI source query on 2026-03-26, `result_status: not_found`)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Abiraterone Acetate is incomplete at multiple critical levels — no predicted indications, no MOA, and no safety information — making it impossible to conduct a meaningful repurposing evaluation at this time.

**To proceed, the following is needed:**

1. **Resolve DG001 (Blocking):** Retrieve prescribing information / package insert warnings and contraindications from the regulatory authority website to enable safety pre-screening
2. **Resolve DG002 (High):** Query DrugBank API to populate MOA, pharmacological categories, and drug targets — the DrugBank query already returned 1 result and should be parsed
3. **Re-run TxGNN pipeline:** Ensure the prediction pipeline completes and populates `predicted_indications` before re-evaluation
5. **Re-run DDI query:** Current DDI result is `not_found`; verify whether drug name normalisation or alternate spellings (e.g., "abiraterone") are needed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

